{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T02:38:02Z","timestamp":1771900682432,"version":"3.50.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.cjca.2020.12.028","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T13:14:37Z","timestamp":1610630077000},"page":"632-643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["A Novel Approach to Medical Management of Heart Failure With Reduced Ejection Fraction"],"prefix":"10.1016","volume":"37","author":[{"given":"Robert J.H.","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan G.","family":"Howlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nowell M.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2020.12.028_bib1","first-page":"234","article-title":"Therapies for advanced heart failure patients ineligible for heart transplantation: beyond pharmacotherapy","volume":"36","author":"Huitema","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib2","first-page":"322","article-title":"Canadian cardiovascular society\/canadian heart failure society joint position statement on the evaluation and management of patients with cardiac amyloidosis","volume":"36","author":"Fine","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib3","first-page":"1015","article-title":"The current role of viability imaging to guide revascularization and therapy decisions in patients with heart failure and reduced left ventricular function","volume":"35","author":"Kandolin","year":"2019","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib4","first-page":"1723","article-title":"Heart failure in adult congenital heart disease: from advanced therapies to end-of-life care","volume":"35","author":"Crossland","year":"2019","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib5","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/0735-1097(94)90385-9","article-title":"Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the registry of studies of left ventricular dysfunction","volume":"23","author":"Benedict","year":"1994","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib6","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-101-3-370","article-title":"The neurohumoral axis in congestive heart failure","volume":"101","author":"Francis","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2020.12.028_bib7","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1161\/01.CIR.0000054164.99881.00","article-title":"Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure trial","volume":"107","author":"Anand","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.12.028_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/S0002-9149(99)00266-0","article-title":"Beta-adrenergic receptor-G protein-adenylyl cyclase signal transduction in the failing heart","volume":"83","author":"Vatner","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib9","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0002-9149(98)00133-7","article-title":"Loss of adrenergic control of the force-frequency relation in heart failure secondary to idiopathic or ischemic cardiomyopathy","volume":"81","author":"Bhargava","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib10","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: Integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2020.12.028_bib11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/01.CIR.103.1.72","article-title":"Aldosterone production is activated in failing ventricle in humans","volume":"103","author":"Mizuno","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.12.028_bib12","first-page":"1208","article-title":"Cardiorenal syndrome and heart failure-challenges and opportunities","volume":"35","author":"Yogasundaram","year":"2019","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1161\/01.RES.85.7.643","article-title":"The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function?","volume":"85","author":"Dostal","year":"1999","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2020.12.028_bib14","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0735-1097(01)01172-X","article-title":"Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects","volume":"37","author":"Brunner-La Rocca","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib15","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/01.CIR.99.16.2113","article-title":"Decreased activity of the l-arginine-nitric oxide metabolic pathway in patients with congestive heart failure","volume":"99","author":"Katz","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.12.028_bib16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/eurjhf\/hfs060","article-title":"Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target?","volume":"14","author":"Cullington","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2020.12.028_bib17","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure","volume":"334","author":"Packer","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2020.12.028_bib18","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2020.12.028_bib19","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/FJC.0b013e31823e5e01","article-title":"Heart rate reduction induced by the if current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia","volume":"59","author":"Fang","year":"2012","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2020.12.028_bib20","first-page":"1282","article-title":"Pharmacologic options for the management of systolic heart failure: examining underlying mechanisms","volume":"31","author":"Mancini","year":"2015","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib21","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1161\/01.CIR.98.25.2911","article-title":"Preserved vasodilator effect of bradykinin in dogs with heart failure","volume":"98","author":"Su","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.12.028_bib22","first-page":"159","article-title":"CCS\/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis","volume":"36","author":"O\u2019Meara","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib23","first-page":"e131","article-title":"Angiotensin receptor-neprilysin inhibition with lcz696: a novel approach for the treatment of heart failure","volume":"9","author":"Langenickel","year":"2012","journal-title":"Drug Discov"},{"key":"10.1016\/j.cjca.2020.12.028_bib24","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2020.12.028_bib25","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1161\/01.RES.0000159937.05502.d1","article-title":"Angiotensin ii and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells","volume":"96","author":"Jaffe","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2020.12.028_bib26","first-page":"1097","article-title":"Spironolactone in acute heart failure patients with renal dysfunction and risk factors for diuretic resistance: from the ATHENA-HF trial","volume":"35","author":"Greene","year":"2019","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib27","doi-asserted-by":"crossref","first-page":"16633","DOI":"10.1074\/jbc.M109.008748","article-title":"Aldosterone stimulates elastogenesis in cardiac fibroblasts via mineralocorticoid receptor-independent action involving the consecutive activation of G\u03b113, c-Src, the insulin-like growth factor-1 receptor, and phosphatidylinositol 3-kinase\/akt","volume":"284","author":"Bunda","year":"2009","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cjca.2020.12.028_bib28","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2020.12.028_bib29","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.cjca.2020.12.028_bib30","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.12.028_bib31","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000362086","article-title":"Ivabradine: Heart rate and left ventricular function","volume":"128","author":"Ferrari","year":"2014","journal-title":"Cardiology"},{"key":"10.1016\/j.cjca.2020.12.028_bib32","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure","volume":"314","author":"Cohn","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2020.12.028_bib33","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2020.12.028_bib34","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","author":"Digitalis Investigation","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2020.12.028_bib35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"GALACTIC-HF Investigators. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2020.12.028_bib36","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (shift)","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2020.12.028_bib37","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1161\/CIRCULATIONAHA.108.812172","article-title":"Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003","volume":"119","author":"Jhund","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.12.028_bib38","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1001\/jamacardio.2019.3593","article-title":"Temporal trends and patterns in mortality after incident heart failure: a longitudinal analysis of 86000 individuals","volume":"4","author":"Conrad","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib39","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ahj.2011.01.027","article-title":"Potential impact of optimal implementation of evidence-based heart failure therapies on mortality","volume":"161","author":"Fonarow","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2020.12.028_bib40","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.105.584102","article-title":"The seattle heart failure model: prediction of survival in heart failure","volume":"113","author":"Levy","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.12.028_bib41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2020.12.028_bib42","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1093\/eurheartj\/ehaa183","article-title":"Effects of dapagliflozin in DAPA-HF according to background heart failure therapy","volume":"41","author":"Docherty","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2020.12.028_bib43","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib44","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2020.12.028_bib45","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jama.2017.10565","article-title":"Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction","volume":"318","author":"Felker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2020.12.028_bib46","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamacardio.2020.0640","article-title":"Assessment of limitations to optimization of guideline-directed medical therapy in heart failure from the guide-it trial","volume":"5","author":"Fiuzat","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib47","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jchf.2020.04.019","article-title":"Care gaps in adherence to heart failure guidelines: clinical inertia or physiological limitations?","volume":"8","author":"Jarjour","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2020.12.028_bib48","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ejhf.1351","article-title":"Medication dosing for heart failure with reduced ejection fraction: opportunities and challenges","volume":"21","author":"Marti","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2020.12.028_bib49","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/ejhf.838","article-title":"The mortality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information leaflets","volume":"19","author":"Zaman","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2020.12.028_bib50","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor lcz696 compared with enalapril on mode of death in heart failure patients","volume":"36","author":"Desai","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2020.12.028_bib51","first-page":"1342","article-title":"2017 comprehensive update of the canadian cardiovascular society guidelines for the management of heart failure","volume":"33","author":"Ezekowitz","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib52","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jama.289.6.712","article-title":"Effects of initiating carvedilol in patients with severe chronic heart failure","volume":"289","author":"Krum","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2020.12.028_bib53","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1388-9842(02)00025-9","article-title":"Rationale and design of the Carvedilol or Metoprolol European Trial in patients with chronic heart failure: COMET","volume":"4","author":"Poole-Wilson","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2020.12.028_bib54","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/jamacardio.2020.2739","article-title":"Association of low-dose triple combination therapy with therapeutic inertia and prescribing patterns in patients with hypertension","volume":"5","author":"Wang","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib55","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cjco.2020.05.009","article-title":"Cost-effectiveness of earlier transition to angiotensin receptor neprilysin inhibitor in patients with heart failure and reduced ejection fraction","volume":"2","author":"Grant","year":"2020","journal-title":"CJC Open"},{"key":"10.1016\/j.cjca.2020.12.028_bib56","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jchf.2018.11.019","article-title":"Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure","volume":"7","author":"Savarese","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2020.12.028_bib57","first-page":"792","article-title":"Baseline functional class and therapeutic efficacy of common heart failure interventions","volume":"31","author":"Miller","year":"2015","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib58","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.amjmed.2019.11.032","article-title":"Growing mismatch between evidence generation and implementation in heart failure","volume":"133","author":"Bhatt","year":"2020","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2020.12.028_bib59","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1161\/CIRCULATIONAHA.115.014281","article-title":"Medication initiation burden required to comply with heart failure guideline recommendations and hospital quality measures","volume":"132","author":"Allen","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.12.028_bib60","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2020.12.028_bib61","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2020.12.028_bib62","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0735-1097(02)01970-8","article-title":"Dose of metoprolol CR\/XL and clinical outcomes in patients with heart failure","volume":"40","author":"Wikstrand","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib63","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/ejhf.580","article-title":"Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction","volume":"18","author":"Vardeny","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2020.12.028_bib64","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.12.028_bib65","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2020.12.028_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212907","article-title":"Higher versus lower doses of ace inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction","volume":"14","author":"Turgeon","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2020.12.028_bib67","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","article-title":"Meta-analysis: Beta-blocker dose, heart rate reduction, and death in patients with heart failure","volume":"150","author":"McAlister","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2020.12.028_bib68","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1093\/eurheartj\/ehi386","article-title":"Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure","volume":"26","author":"Metra","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2020.12.028_bib69","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/eurjhf\/hfr020","article-title":"Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure","volume":"13","author":"Dungen","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2020.12.028_bib70","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1093\/eurheartj\/ehi409","article-title":"Prognostic benefit of beta-blockers in patients not receiving ACE inhibitors","volume":"26","author":"Krum","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2020.12.028_bib71","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/ejhf.1869","article-title":"Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction","volume":"22","author":"Ouwerkerk","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2020.12.028_bib72","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure","volume":"78","author":"Pitt","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib73","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/ejhf.1400","article-title":"Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial","volume":"21","author":"Ferreira","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2020.12.028_bib74","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2020.12.028_bib75","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ahj.2019.12.024","article-title":"Predischarge initiation of ivabradine in the management of heart failure","volume":"223","author":"Mentz","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2020.12.028_bib76","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijcard.2017.12.093","article-title":"Optimization of heart rate lowering therapy in hospitalized patients with heart failure: insights from the optimize heart failure care program","volume":"260","author":"Lopatin","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib77","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1161\/CIRCULATIONAHA.120.051863","article-title":"An electronically delivered, patient-activation tool for intensification of medications for chronic heart failure with reduced ejection fraction: the EPIC-HF trial","volume":"143","author":"Allen","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.12.028_bib78","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/clc.23291","article-title":"Rationale and design of a navigator-driven remote optimization of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction","volume":"43","author":"Blood","year":"2020","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib79","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/ejhf.1503","article-title":"Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial","volume":"21","author":"Schulz","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2020.12.028_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamacardio.2020.3757","article-title":"Remote optimization of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction","volume":"5","author":"Desai","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib81","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archinte.161.2.165","article-title":"Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial","volume":"161","author":"Massie","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2020.12.028_bib82","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jchf.2015.10.008","article-title":"Tolerability and feasibility of beta-blocker titration in HFpEF versus HFrEF","volume":"4","author":"Edelmann","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2020.12.028_bib83","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2020.12.028_bib84","first-page":"531","article-title":"CCS\/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction","volume":"37","author":"McDonald","year":"2021","journal-title":"Can J Cardiol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X21000465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X21000465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:46:42Z","timestamp":1760107602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X21000465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0828282X21000465"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2020.12.028","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Novel Approach to Medical Management of Heart Failure With Reduced Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2020.12.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}